Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma
Simon Le Gallou(Inserm), Mikaël Roussel(Inserm), Karin Tarte(Inserm), Steven Le Gouill(Inserm), Anna Mingam(Centre Hospitalier Universitaire de Rennes), Juliette Ferrant(Inserm), Roch Houot(Inserm), Guillaume Cartron(Hôpital Saint Eloi), Thierry Lamy(Centre Hospitalier Universitaire de Lille), Jonathan M. Irish(Vanderbilt University), Céline Monvoisin(Inserm), Olivier Casasnovas, Thierry Fest(Inserm), Pascal Godmer(Centre hospitalier Bretagne Atlantique), Krimo Bouabdallah(Centre Hospitalier Universitaire de Bordeaux), Delphine Rossille(Inserm), Thierry Jo Molina(Hôpital Necker-Enfants Malades), Imane Azzaoui(Centre Hospitalier Universitaire de Rennes), Gandhi Damaj, Faustine Lhomme(Centre Hospitalier Universitaire de Rennes), Céline Pangault(Inserm)
Cited by 18
Related Papers
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718